Genenta Science SpA is an Italian biotechnology company that was founded in 2014 with the mission to develop gene therapy for cancer treatment. The company has its headquarters in Milan, Italy, and is publicly listed on the AIM Italia stock exchange. Genenta Science is focused on creating a new class of gene therapy using autologous hematopoietic stem cells (HSCs) modified to express therapeutic genes, with the goal of providing targeted treatment for cancer patients.
The company’s proprietary platform technology, Temferon, is based on the use of gene vectors that are designed to deliver therapeutic genes specifically to tumors, using a patient’s own HSCs. Temferon is a first-in-class product that is based on a dual mechanism of action, utilizing a proprietary chimeric antigen receptor (CAR) to specifically target cancer cells, and a proprietary human interferon alpha (hIFNα) to modulate the immune system.
Genenta Science’s gene therapy approach is still in the clinical trial phase, with ongoing trials focused on patients with glioblastoma, a type of brain cancer, and multiple myeloma, a type of blood cancer. The company has also recently announced plans to expand the use of the Temferon platform to treat solid tumors, such as pancreatic cancer and colorectal cancer.